Experienced in Hepatic Venoocclusive Disease with Immunodeficiency

Stavroula Levrat-Masouridi

Geneve, GE, CH 
Experienced in Hepatic Venoocclusive Disease with Immunodeficiency
Geneve, GE, CH 
OverviewLocationsClinical Research

Overview

Stavroula Levrat-Masouridi practices in Geneve, Switzerland. Ms. Levrat-Masouridi is rated as an Experienced expert by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. Her top areas of expertise are Graft Versus Host Disease (GvHD), Cytomegalovirus Infection, Cytomegalic Inclusion Disease, Bone Marrow Transplant, and Bone Graft.

Her clinical research consists of co-authoring 84 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Hepatic Venoocclusive Disease with Immunodeficiency.

Gender
Female

Locations

Geneve, GE, Switzerland
Other Locations
Bern, BE, Switzerland
Basel, BS, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin
Study Phase: Phase 3

84 Total Publications

Blood Virome After Allogeneic Hematopoietic Stem Cell Transplantation.
Blood Virome After Allogeneic Hematopoietic Stem Cell Transplantation.
Journal: Open forum infectious diseases
Published: March 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Levrat-Masouridi's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile